Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

New products to underpin growth into 2024

Control Bionics
3:27pm
February 7, 2024
Following a successful A$2.7m rights issue, CBL is now funded into 2024 with new products (DROVE and NeuroStrip) adding to the improving sales position. Australia delivered solid revenue growth in 1H24 (despite NDIS delays) and momentum is expected to continue in 2H. However, sales in North America in 1H24 were flat although management expects an improvement in 2H. We are moving a number of our early stage development companies to the new ‘Keeping Stock’ format which enables us to continue to provide regular and timely updates. We will cease providing a rating, valuation and forecasts. Therefore, our previous forecasts, target price and recommendation should no longer be relied upon for investment decisions.

Remaining steady

Dexus Convenience Retail REIT
3:27pm
February 6, 2024
DXC’s 1H24 result delivered stable portfolio metrics with the focus during the half on maintaining balance sheet resilience. Gearing at c32%. Dec-23 revaluations saw cap rates expand 20bps (-1.7% portfolio impact). NTA stands at $3.63 vs $3.75 at Jun-23. FY24 guidance has been tightened slightly and now comprises FFO and DPS of 20.8-21.1c (was 20.7-21.1c). This equates to a distribution yield of approx. 8%. DXC remains an Add with a revised price target of $3.23.

More than a gut feeling

Microba Life Sciences
3:27pm
February 6, 2024
Microba Life Sciences (MAP) is an emerging leader in the microbiome industry specialising in gut health testing and therapeutic development. The company provides a comprehensive end-to-end solution, encompassing internally developed tests and therapeutic candidates generated via its discovery engine and artificial intelligence (AI) capabilities. In collaboration with renowned microbiome specialists worldwide, MAP stands out as a distinctive value proposition, offering high-margin products and opportunities through its therapeutics discovery platform. The expanding testing services business and increasing awareness among healthcare professionals about the pivotal role of the microbiome are driving a surge in demand. This heightened awareness is fueling increased interest in microbiome-related services, products, and advancements, indicating a growing recognition of its impact on overall health across diverse medical applications. We initiate coverage of MAP with a valuation and target price of A$0.35 p/s with a Speculative Buy recommendation.

Building towards the next earnings step-up

Pinnacle Investment Mgmt
3:27pm
February 2, 2024
Group NPAT was flat on the pcp at A$30.2m and in line with expectations. Affiliate NPAT contribution was +31% on pcp but -9% ex-performance fees. Group FUM closed at A$100.1bn, up 9% over the half. Starting 2H24 FUM is up ~8% on 1H24 average (flows and market uplift late in the half). 1H24 Net flows comprised: retail +A$1.8bn; domestic insto -A$0.4bn; and offshore +A$3.1bn. QoQ improvement was experienced (1Q A$0.2bn; 2Q A$4.3bn). PNI’s near-term valuation (~26x FY24 PE) sees the stock susceptible to short-term volatility. However, PNI has structural growth drivers and we see the medium-term (FY25/26) earnings step-up is supported by: a return to improved flows; higher performance fee FUM; significant operating leverage on improved FUM; leveraging the recent investment spend; and the eventual addition of new managers.

Executing its strategy

MoneyMe
3:27pm
February 1, 2024
MoneyMe (MME) has released a 1H24 trading update, which whilst brief, did highlight the continued execution of management’s strategy to improve the overall credit quality of the book itself (average Equifax score 741) and focus on profitability. The gross loan book remained stable at A$1.2bn, generating revenue of >A$105m (-~13% on pcp) and a statutory NPAT of A$6m. Our FY24F-FY26F EBITDA is lowered by ~3-9% on slight adjustments to gross loan book growth rates, loss rates and book yield. Our DCF/PB blended valuation (equal-weighted) and price target remains unchanged at A$0.25 on the above changes offset by timing impacts of our DCF.

Execution in the US required

Credit Corp
3:27pm
January 31, 2024
CCP’s 1H24 underlying NPAT of A$33.5m (+5% on pcp) missed consensus expectations (>15%) on higher lending provisioning; and high cost growth. CCP held NPAT guidance. The mid-point looks achievable (implied 2H24 NPAT ~A$51.5m), with 2H Lending volumes the main swing factor. Despite the ‘miss’, CCP’s FY25/26 earnings outlook remains largely unchanged. However, the composition skews further to Consumer Lending; and trust in the USA execution is required (only slight incremental US ‘evidence’ in this result). Backing management’s execution in delivering on USA divisional growth expectations over FY25/26 is needed. We think the valuation point (11.5x FY25PE) provides enough upside and risk/reward to do so. Add maintained.

Hitting its targets

Airtasker
3:27pm
January 31, 2024
Airtasker (ART) released a broadly positive 2Q24 trading update in our view, which saw an +8% increase in group revenue to A$12.2m, and the business achieving positive free cash flow for the period. We make upward revisions to our FY25-26F revenue estimates on an improved take-rate (details below). Our DCF/Multiples derived price target increases marginally to A$0.54 (from A$0.53). Add maintained.

Share price over reaction to an exciting outlook

ImpediMed
3:27pm
January 31, 2024
IPD share price has come under selling pressure after the release of its 2Q24 cashflow report which was below expectation. However we believe this is an overreaction with excellent progress being made with private payor coverage. IPD highlight that 13 states in the US have reached critical mass (ie 80% of population covered for reimbursement from private payors or Medicare). The target is that 85% of the US will be providing coverage by the end of FY24. Following a change in management estimates of revenue recognition to equal monthly payments across the term of each contract we have revised our revenue forecast. As a result our DCF based valuation has reduced to A$0.20 (was A$0.22). we maintain our Speculative Buy recommendation.

4Q23 report card

Atlas Arteria
3:27pm
January 30, 2024
The 4Q23 traffic and toll revenue data presented minimal surprises on the key roads that contribute to the bulk of ALX’s equity valuation. 12 month target price lifts 3 cps to $5.61, mostly driven by higher Chicago Skyway toll escalation for FY24 and FY25 than previously assumed. HOLD retained, albeit value does look attractive at current prices with c.10% potential TSR (underwritten by a c.7% cash yield).

Good progress on all fronts

Micro-X
3:27pm
January 30, 2024
MX1 posted its 2Q24 report which showed a net operating cash inflow of A$4.3m which was boosted by the receipt of a R&D rebate of A$6.2m. Pleasingly, Mobile DR receipts are ticking up and project work with the ASA and DHA remain on track. Our focus remains on turning customer and distributor demonstrations of the Argus into sales. At this stage we have made no changes to our forecasts, valuation or target price of A$0.27. We maintain a Speculative Buy recommendation.

News & Insights

Treasury Secretary Scott Bessent’s adept negotiation of a US-China tariff deal and his method for assessing tariffs’ modest impact on inflation, using a 20.5% effective rate, position him as a formidable successor to Henry Morganthau’s legacy.

In the 1930s, the US Treasury Secretary Henry Morganthau was widely regarded as the finest Treasury Secretary since Alexander Hamilton. However, if the current Treasury Secretary Scott Bessent, continues to deliver results as he is doing now, he will provide formidable competition to Morganthau’s legacy.

The quality of Bessent’s work is exceptional, demonstrated by his ability to secure an agreement with China in just a few days in complex circumstances.

The concept of the "effective tariff rate" is a term that has gained traction recently. Although nominal tariff rates on individual goods in individual countries might be as high as 100% or 125%; the effective tariff rate, which reflects the actual tariffs the US imposes on imports from all countries, is thought to be only 20.5%. This figure comes from an online spreadsheet published by Fitch Ratings, since 24 April.

Finch Ratings Calculator Screenshot

This effective tariff rate of 20.5% can be used in assessing the impact of import tariffs on US inflation. To evaluate this, I used a method proposed by Scott Bessent during his Senate confirmation hearing. Bessent began by noting that imports account for only 16% of US goods and services that are consumed in the US Economy. In this case, a 10% revenue tariff would increase domestic prices by just 1.6%. With a core inflation rate of 2.8% in the US, this results in a headline inflation rate of 4.4%. Thus, the overall impact of such tariffs on the US economy is relatively modest.

A couple of weeks ago, Austan Goolsbee, the President of the Chicago Fed, noted that tariffs typically increase inflation, which might prompt the Fed to lift rates, but they also reduce economic output, which might prompt the Fed to rate cuts. Consequently, Goolsbee suggested that the Federal Reserve might opt to do nothing. This prediction was successful when the Open Market Committee of the Fed, with Goolsbee as a member, left the Fed Funds rate unchanged last week.

A 90-day agreement between the US and China, masterfully negotiated by Scott Bessent, has dramatically reduced tariffs between China and the US. China now only imposes a 10% import tariff on the US, while the US applies a 30% tariff on Chinese goods—10% as a revenue tariff and 20% to pressure China to curb the supply of fentanyl ingredients to third parties in Mexico or Canada. It is this fentanyl which fuels the US drug crisis. This is a priority for the Trump administration.

How Import Tariffs Affect US Inflation.

We can calculate how much inflation a tariff adds to the US economy in the same way as Scott Bessent by multiplying the effective tariff rate by the proportion that imports are of US GDP. Based on a 20.5% US effective tariff rate, I calculated that it adds 3.28% to the US headline Consumer Price Index (CPI). This results in a US headline inflation rate of 6.1% for the year ahead. In Australia, we can draw parallels to the 10% GST introduced 24 years ago, where price effects were transient and vanished after a year, avoiding sustained high inflation.

Before these negotiations, the US was levying a nominal tariff on China of 145%. Some items were not taxed, so meant that the effective tariff on China was 103%. Levying this tariff meant that the US faced a price effect of 3.28%, contributing to a 6.1% headline inflation rate.

If the nominal tariff rate dropped to 80%, the best-case scenario I considered previously, the price effect would fall to 2.4%, with a headline US inflation rate of 5.2%. With the US now charging China a 30% tariff, this adds only 2% to headline inflation, yielding a manageable 4.8% US inflation rate.

As Goolsbee indicated, the Fed might consider raising interest rates to counter inflation or cutting them to address reduced output, but ultimately, it is likely to maintain current rates, as it did last week. I anticipate the Fed will continue to hold interest rates steady but with an easing bias, potentially cutting rates in the second half of the year once the situation stabilises.

My current Fed Funds rate model suggests that, absent this year's tariff developments, the Fed would have cut rates by 50 basis points. This could be highly positive for the US economy.

Read more
In a lively presentation to the Economic Club of New York, Federal Reserve Bank of Chicago President Austan Goolsbee highlighted tariffs as a minor stagflation risk but emphasized strong U.S. GDP growth of around 2.6%, suggesting a resilient economy and potential for a soft landing.

I’d like to discuss a presentation delivered by Austan Goolsbee, President of the Federal Reserve Bank of Chicago, to the Economic Club of New York on 10 April. Austan Goolsbee, gave a remarkably animated talk about tariffs and their impact on the U.S. economy.

Goolsbee is a current member of the Federal Reserve’s Open Market Committee, alongside representatives from Washington, D.C., and Fed bank Presidents from Chicago, Boston, St. Louis, and Kansas City.  

Having previously served as Chairman of the Council of Economic Advisers in the Obama White House, Goolsbee’s presentation style in New York was notably different from his more reserved demeanour I had previously seen when I had attended a talk of his in Chicago.

During his hour-long, fast-paced talk, Goolsbee addressed the economic implications of tariffs. He recounted an interview where he argued that raising interest rates was not the appropriate response to tariffs, a stance that led some to label him a “Dove.” He humorously dismissed the bird analogy, instead likening himself to a “Data Dog,” tasked with sniffing out the data to guide decision-making.

Goolsbee explained that tariffs typically drive inflation higher, which might ordinarily prompt rate hikes. However, they also tend to reduce economic growth, suggesting a need to cut rates. This creates a dilemma where rates might not need adjustment at all. He described tariffs as a “stagflation event” but emphasised that their impact is minor compared to the severe stagflation of the 1970s.

When asked if the U.S. was heading towards a recession, Goolsbee said that the "hard data" was surprisingly strong.

Let us now look at our model of US GDP based on the Chicago Fed National Activity Index. This Index   incorporates 85 variables across production, sales, employment, and personal consumption.  In the final quarter of last year, this index indicated the GDP growth was slightly below the long-term average, suggesting a US GDP growth rate of 1.9% to 2%.

However, data from the first quarter of this year showed stronger growth, just fractionally below the long-term trend.

Using Our Chicago Fed model, we find that US GDP growth had risen from about 2% growth to a growth rate of around 2.6%, indicating a robust U.S. economy far from recessionary conditions.

Model of US GDP

We think that   increased government revenue from Tariffs might temper domestic demand, potentially guiding growth down towards 1.9% or 2% by year’s end. Despite concerns about tariffs triggering a downturn, this highlights the economy’s resilience and suggests   a “soft landing,” which could allow interest rates to ease, weaken the U.S. dollar, and boost demand for equities.

We will provide monthly reviews of these indicators. We note that, for now, the outlook for the U.S. economy remains very positive.

Read more
This discussion simplifies the US business cycle, highlighting how tariffs are projected to lower growth to 1.8% in 2025, reduce the budget deficit, and foster an extended soft landing, boosting equities and commodities through 2027.


I want to discuss a simplified explanation of the US business cycle, prompted by the International Monetary Fund's forecast released yesterday, which, for the first time, assessed the impact of tariffs on the US economy. Unlike last year's 2.8% growth, the IMF predicts a drop to 1.8% in 2025. This is slightly below my forecast of 1.9 to 2%. They further anticipate growth will decline to 1.7% in 2026, lower than my previous estimate of 2%. Growth then returns to 2% by 2027.

This suggests that increased tariffs will soften demand, but the mechanism is intriguing. Tariffs are expected to reduce the US budget deficit from about 7% of GDP to around 5%, stabilizing government debt, though more spending cuts are needed.  This reduction in US deficit reduces US GDP growth. This leads to a slow down.

The revenue from tariffs is clearly beneficial for the US budget deficit, but the outlook for the US economy now points to an extended soft landing. This is the best environment for equities and commodities over a two-year view. With below-trend growth this year and even softer growth next year, interest rates are expected to fall, leading the fed funds rate to drift downward in response to slower growth trends. Additionally, the US dollar is likely to weaken as the Fed funds rate declines, following a traditional US trade cycle model: falling interest rates lead to a weaker currency, which in turn boosts commodity prices.

This is particularly significant because the US is a major exporter of agricultural commodities, has rebuilt its oil industry, and is exporting LNG gas. The rising value of these commodities stimulates the economy, boosting corporate profits and setting the stage for the next surge in growth in a couple of years.

This outlook includes weakening US interest rates and rising commodity prices, continuing through the end of next year. This will be combined with corporate tax cuts, likely to be passed in a major bill in July, reducing US corporate taxes from 21% to 15%.  This outlook is very positive for both commodities and equities. Our model of commodity prices shows an upward movement, driven by an increase in international liquidity within the international monetary system.

With US dollar debt as the largest component in International reserves , as US interest rates fall, the creation of US government debt accelerates, increasing demand for commodities.  The recent down cycle in commodities is now transitioning to an extended upcycle through 2026 and 2027, fueled by this increased liquidity due to weaker interest rates.

Furthermore, the rate of growth in international reserves is accelerating, having reached a long-term average of about 7% and soon expected to rise to around 9%. Remarkably, the tariffs are generating a weaker US dollar, which drives the upward movement in commodity prices. This improvement in commodity prices is expected to last for at least the next two years, and potentially up to four years.

Read more